Regeneron (REGN) Lower as Germany's IQWiG Questions Eylea's Effectiveness
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Join SI Premium – FREE
Regeneron (Nasdaq: REGN) is lower Thursday following news that the effectiveness of Eylea, its collaboration with Bayer HealthCare, is being questioned in a key European market.
Reuters said that the German Institute for Quality and Efficiency in Health Care (IQWiG) was unable to determine whether or not Eylea was superior to Novartis' (NYSE: NVS) Lucentis as a treatment for macular edema. The committee said trials for Eylea and Lucentis weren't comparable because neither drug was being administered the way regulators specified.
Germany's medical cost-benefit agency G-BA will publish its cost-benefit analysis on Eylea within the next three months, though Bayer expects to issue a response within three weeks.
Reuters said that the German Institute for Quality and Efficiency in Health Care (IQWiG) was unable to determine whether or not Eylea was superior to Novartis' (NYSE: NVS) Lucentis as a treatment for macular edema. The committee said trials for Eylea and Lucentis weren't comparable because neither drug was being administered the way regulators specified.
Germany's medical cost-benefit agency G-BA will publish its cost-benefit analysis on Eylea within the next three months, though Bayer expects to issue a response within three weeks.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron reports 73% response rate for ubamatamab in ovarian cancer
- BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
- Regeneron Pharma (REGN) PT Raised to $930 at Jefferies
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
